7/27/21
The FDA approved last week this newest conjugate vaccine pneumococcal 15-valent, Vaxneuvance™ manufactured by Merck. Now, finally more vaccine options are available for the prevention of invasive pneumoccocal disease caused by Streptococcus pneumoniae.